| Japanese gastric cancer treatment guidelines 2018 (5th edition) | Gastric Cancer | 2021 | 484 |
| Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19 | Gut | 2021 | 312 |
| Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study | Gastroenterology | 2021 | 285 |
| Epidemiology of Hepatocellular Carcinoma | Hepatology | 2021 | 272 |
| Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention | Nature Reviews Gastroenterology and Hepatology | 2021 | 228 |
| STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD | Gastroenterology | 2021 | 191 |
| Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19 | Gut | 2021 | 180 |
| The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics | Nature Reviews Gastroenterology and Hepatology | 2021 | 165 |
| Molecular and cellular mechanisms of liver fibrosis and its regression | Nature Reviews Gastroenterology and Hepatology | 2021 | 152 |
| Esophageal motility disorders on high-resolution manometry: Chicago classification version 4.0 | Neurogastroenterology and Motility | 2021 | 146 |
| Effect of IBD medications on COVID-19 outcomes: results from an international registry | Gut | 2021 | 140 |
| Liver regeneration: biological and pathological mechanisms and implications | Nature Reviews Gastroenterology and Hepatology | 2021 | 114 |
| Advances in immunotherapy for hepatocellular carcinoma | Nature Reviews Gastroenterology and Hepatology | 2021 | 113 |
| Impact of the COVID-19 pandemic on UK endoscopic activity and cancer detection: a National Endoscopy Database Analysis | Gut | 2021 | 112 |
| From NAFLD to MAFLD: Implications of a Premature Change in Terminology | Hepatology | 2021 | 111 |
| Potential intestinal infection and faecal-oral transmission of SARS-CoV-2 | Nature Reviews Gastroenterology and Hepatology | 2021 | 107 |
| The four epidemiological stages in the global evolution of inflammatory bowel disease | Nature Reviews Gastroenterology and Hepatology | 2021 | 101 |
| Gut microbiota-derived metabolites as central regulators in metabolic disorders | Gut | 2021 | 101 |
| ACG Clinical Guideline: Management of Irritable Bowel Syndrome | American Journal of Gastroenterology | 2021 | 98 |
| Liver Biochemistries in Hospitalized Patients With COVID-19 | Hepatology | 2021 | 98 |
| Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching | Gut | 2021 | 98 |
| Dietary fibre in gastrointestinal health and disease | Nature Reviews Gastroenterology and Hepatology | 2021 | 95 |
| Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort | Gut | 2021 | 94 |
| Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD | Gut | 2021 | 93 |
| COVID-19 and liver disease: mechanistic and clinical perspectives | Nature Reviews Gastroenterology and Hepatology | 2021 | 90 |
